Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Justin F. Gainor(Massachusetts General Hospital), Giuseppe Curigliano(University of Milan), Dong‐Wan Kim(Seoul National University Hospital), Ki Hyeong Lee(Ulsan College), Benjamin Besse(Université Paris-Saclay), Christina S. Baik(University of Washington), Robert C. Doebele(University of Colorado Denver), Philippe A. Cassier(Centre Léon Bérard), Gilberto Lopes(University of Miami), Daniel S.W. Tan(National Cancer Centre Singapore), Elena Garralda(Vall d'Hebron Hospital Universitari), Luis Paz‐Ares(Centro de Investigación del Cáncer), Byoung Chul Cho(Yonsei University), Shirish M. Gadgeel(University of Michigan), Michael Thomas(Heidelberg University), Stephen V. Liu(Georgetown University), Matthew H. Taylor(Providence Portland Medical Center), Aaron S. Mansfield(Mayo Clinic in Arizona), Viola W. Zhu(University of California, Irvine), Corinne Clifford(Blueprint Medicines (United States)), Hui Zhang(Blueprint Medicines (United States)), Michael Palmer(Blueprint Medicines (United States)), Jennifer Green(Blueprint Medicines (United States)), Christopher D. Turner(Blueprint Medicines (United States)), Vivek Subbiah(The University of Texas MD Anderson Cancer Center)
Cited by 441Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis